CL2009000236A1 - Compuestos derivados de triazolopiridazina, inhibidores de par1,procedimiento de preparacion y uso para profilaxis, prevencion y tratamiento de enfermedades asociadas con trombosis, embolia, hipercoagulabilidad, cambios fibroticos o trastornos inflamatorios. - Google Patents

Compuestos derivados de triazolopiridazina, inhibidores de par1,procedimiento de preparacion y uso para profilaxis, prevencion y tratamiento de enfermedades asociadas con trombosis, embolia, hipercoagulabilidad, cambios fibroticos o trastornos inflamatorios.

Info

Publication number
CL2009000236A1
CL2009000236A1 CL2009000236A CL2009000236A CL2009000236A1 CL 2009000236 A1 CL2009000236 A1 CL 2009000236A1 CL 2009000236 A CL2009000236 A CL 2009000236A CL 2009000236 A CL2009000236 A CL 2009000236A CL 2009000236 A1 CL2009000236 A1 CL 2009000236A1
Authority
CL
Chile
Prior art keywords
triazolopyridazine
hypercoagulability
embolism
thrombosis
prophylaxis
Prior art date
Application number
CL2009000236A
Other languages
English (en)
Inventor
Wolkmar Wehner
Uwe Heinelt
Matthias Hermann
Karl Schoenafinger
Henning Steinhagen
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CL2009000236A1 publication Critical patent/CL2009000236A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCIóN SE REFIERE A COMPUESTOS DERIVADOS DE TRIAZOLOPIRIDAZINAS DE FÓRMULA (I), DONDE<br /> R1-R8 Y 01-03 SE DEFINEN EN LA MEMORIA DESCRIPTIVA, CON ACTIVIDAD ANTITROMBÓTICA, QUE INHIBEN<br /> ESPECIALMENTE EL RECEPTOR 1 ACTIVADO POR PROTEASA , A PROCEDIMIENTOS DE PREPARACIÓN Y A SU USO<br /> PARA PREPARAR MEDICAMENTOS<br />  
CL2009000236A 2008-02-05 2009-02-03 Compuestos derivados de triazolopiridazina, inhibidores de par1,procedimiento de preparacion y uso para profilaxis, prevencion y tratamiento de enfermedades asociadas con trombosis, embolia, hipercoagulabilidad, cambios fibroticos o trastornos inflamatorios. CL2009000236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290112 2008-02-05

Publications (1)

Publication Number Publication Date
CL2009000236A1 true CL2009000236A1 (es) 2009-06-05

Family

ID=39539711

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000236A CL2009000236A1 (es) 2008-02-05 2009-02-03 Compuestos derivados de triazolopiridazina, inhibidores de par1,procedimiento de preparacion y uso para profilaxis, prevencion y tratamiento de enfermedades asociadas con trombosis, embolia, hipercoagulabilidad, cambios fibroticos o trastornos inflamatorios.

Country Status (32)

Country Link
US (2) US8076336B2 (es)
EP (1) EP2240487B1 (es)
JP (1) JP5526040B2 (es)
KR (1) KR20100114514A (es)
CN (1) CN101981034B (es)
AR (1) AR070410A1 (es)
AT (1) ATE537172T1 (es)
AU (1) AU2009211887B2 (es)
BR (1) BRPI0907486A2 (es)
CA (1) CA2713550C (es)
CL (1) CL2009000236A1 (es)
CO (1) CO6260083A2 (es)
CY (1) CY1113228T1 (es)
DK (1) DK2240487T3 (es)
ES (1) ES2379447T3 (es)
HK (1) HK1149011A1 (es)
HR (1) HRP20120230T1 (es)
IL (1) IL207205A0 (es)
MA (1) MA32061B1 (es)
MX (1) MX2010008490A (es)
MY (1) MY152040A (es)
NZ (1) NZ587141A (es)
PA (1) PA8814801A1 (es)
PE (1) PE20091455A1 (es)
PL (1) PL2240487T3 (es)
PT (1) PT2240487E (es)
RS (1) RS52264B (es)
RU (1) RU2499797C2 (es)
SI (1) SI2240487T1 (es)
TW (1) TW200946532A (es)
WO (1) WO2009097970A1 (es)
ZA (1) ZA201004467B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101796056A (zh) * 2006-09-18 2010-08-04 沃泰克斯药物股份有限公司 c-MET的杂环抑制剂及其用途
NZ587142A (en) 2008-02-05 2012-04-27 Sanofi Aventis Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
US8673890B2 (en) 2009-10-29 2014-03-18 Janssen Pharmaceutica Nv 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578464A (en) 1983-11-22 1986-03-25 Merrell Dow Pharmaceuticals Inc. 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds
CN1046517C (zh) * 1994-09-16 1999-11-17 武田药品工业株式会社 三唑并哒嗪,其制备和应用
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
EP1614680B1 (en) * 2001-04-19 2011-12-21 Eisai R&D Management Co., Ltd. Process for preparing 2-iminopyrrolidine derivatives
US6956046B2 (en) 2001-05-25 2005-10-18 Mochida Pharmaceutical Co., Ltd. 4-hydroxypiperidine derivatives having analgesic activity
WO2003031442A1 (fr) 2001-10-05 2003-04-17 Takeda Chemical Industries, Ltd. Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation
PL371948A1 (en) 2001-10-18 2005-07-11 Schering Corporation Himbacine analogues as thrombin receptor antagonists
EP1860106B1 (en) 2002-04-16 2010-01-20 Schering Corporation Tricyclic thrombin receptor antagonists
CN100439336C (zh) 2003-02-19 2008-12-03 卫材R&D管理有限公司 制备环状苯甲脒衍生物的方法
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
EP1813282A4 (en) 2004-11-09 2011-03-02 Eisai R&D Man Co Ltd MEANS FOR THE TREATMENT OF ANGIOSPASM IN SUBARACHO-OAL BLOODING WITH THROMBIN RECEPTOR ANTAGONIST AS AN ACTIVE AGENT
KR101412675B1 (ko) * 2005-12-21 2014-07-03 얀센 파마슈티카 엔.브이. 티로신 키나제 모듈레이터로서의 트리아졸로피리다진
DE102006025318A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung
DE102006036023A1 (de) * 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
JP2011511018A (ja) 2008-02-05 2011-04-07 サノフィ−アベンティス Ｐａｒ１阻害剤としてのｓｆ５誘導体、その製造、及び薬剤としての使用
AU2009211890B2 (en) * 2008-02-05 2014-03-13 Sanofi-Aventis Imidazopyridazines as PAR1 inhibitors, production thereof, and use thereof as medicaments
NZ587142A (en) * 2008-02-05 2012-04-27 Sanofi Aventis Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2009126624A1 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
US8394823B2 (en) 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors

Also Published As

Publication number Publication date
TW200946532A (en) 2009-11-16
CA2713550C (en) 2016-06-14
AR070410A1 (es) 2010-04-07
MA32061B1 (fr) 2011-02-01
PA8814801A1 (es) 2009-09-17
CN101981034B (zh) 2013-08-14
RU2499797C2 (ru) 2013-11-27
AU2009211887A1 (en) 2009-08-13
PE20091455A1 (es) 2009-10-22
ZA201004467B (en) 2011-09-28
CA2713550A1 (en) 2009-08-13
BRPI0907486A2 (pt) 2015-07-14
PL2240487T3 (pl) 2012-05-31
NZ587141A (en) 2012-04-27
AU2009211887B2 (en) 2013-09-19
US20110034451A1 (en) 2011-02-10
MX2010008490A (es) 2010-08-18
US9079906B2 (en) 2015-07-14
ATE537172T1 (de) 2011-12-15
JP5526040B2 (ja) 2014-06-18
CO6260083A2 (es) 2011-03-22
MY152040A (en) 2014-08-15
JP2011511016A (ja) 2011-04-07
PT2240487E (pt) 2012-03-08
US8076336B2 (en) 2011-12-13
US20120010203A1 (en) 2012-01-12
RS52264B (en) 2012-10-31
WO2009097970A1 (de) 2009-08-13
DK2240487T3 (da) 2012-04-02
RU2010136957A (ru) 2012-03-20
IL207205A0 (en) 2010-12-30
ES2379447T3 (es) 2012-04-26
HK1149011A1 (en) 2011-09-23
SI2240487T1 (sl) 2012-04-30
CN101981034A (zh) 2011-02-23
EP2240487B1 (de) 2011-12-14
CY1113228T1 (el) 2016-04-13
HRP20120230T1 (hr) 2012-04-30
KR20100114514A (ko) 2010-10-25
EP2240487A1 (de) 2010-10-20

Similar Documents

Publication Publication Date Title
UY32820A (es) Composiciones dermatologicas de antagonistas del receptor dp2
CR10309A (es) &#34;compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1&#34;
CO6450655A2 (es) Atropisómeros de derivados de 2-purinil-3-tolil-quinazolinona y métodos de uso
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
NO20083568L (no) Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser
UY36215A (es) Espirocicloheptanos como inhibidores de rock
MA32393B1 (fr) Composés et compositions servant d&#39;inhibiteurs de kinases
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
EA201171493A1 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
TR201901886T4 (tr) DNA-PK inhibitörleri.
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CO6690805A2 (es) 6-amino-nicotinamidas sustituidas como modulares de kcnq2/3
MX2012010404A (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de enfermedades.
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CL2007001901A1 (es) Compuestos derivados de acido carboxilico de naftaleno, quinolina y benzo[b]tiofeno sustituidos, inhibidores de cxcr2; composiicon farmaceutica; y uso para el tratamiento o profilaxis de enfermedades mediadas por quimioquinas, tales como enfermedades inflamatorias agudas y cronicas
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CL2007002427A1 (es) Compuestos derivados heterociclicos, inhibidores de metaloproteinasa de matriz; proceso de preparacion; composicion farmaceutica, util para el tratamiento o profilaxis de enfermedades inflamatorias o desordenes autoinmunes.